Mutya Harsch
CIK 1727809 · CHIEF LEGAL OFFICER AND GC · last filed 2026-04-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$79.1K
Companies
4
Total Filings
50
Lifetime Open-Market Net
$14.1K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VYNE | CHIEF LEGAL OFFICER AND GC | 121,898 | $0.65 | $79.1K | $25.0K | 32 | 2026-04-02 |
| Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Director | — | $1.10 | — | $0 | 3 | 2023-06-08 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Chief Legal Officer and GC | 318,887 | — | — | $0 | 5 | 2020-07-02 |
| Foamix Pharmaceuticals Ltd. (FOMX) Delisted | CLO and General Counsel | 98,232 | — | — | -$10.9K | 9 | 2020-03-03 |
Recent Filings · Page 4 of 5
50 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-04-02 | VYNE | Tax (F) | −1,765 | -$12.1K | EDGAR |
| 2021-02-24 | VYNE | Grant (A) | +29,213 | $0 | EDGAR |
| 2021-01-05 | VYNE | Tax (F) | −1,822 | -$2.9K | EDGAR |
| 2020-12-02 | VYNE | Grant (A) | +10,460 | $15.1K | EDGAR |
| 2020-10-02 | VYNE | Tax (F) | −1,822 | -$3.0K | EDGAR |
| 2020-07-02 | VYNE Therapeutics Inc. (MNLO) Delisted | Tax (F) | −1,822 | -$3.2K | EDGAR |
| 2020-05-08 | VYNE Therapeutics Inc. (MNLO) Delisted | Grant (A) | +150,000 | $0 | EDGAR |
| 2020-04-07 | VYNE Therapeutics Inc. (MNLO) Delisted | Mixed | +114,209 | -$6.3K | EDGAR |
| 2020-04-02 | VYNE Therapeutics Inc. (MNLO) Delisted | Tax (F) | −1,688 | -$4.5K | EDGAR |
| 2020-03-11 | — | Disp (D) | −98,232 | $0 |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.